Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Item bank

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Item bank. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-001594-25 Sponsor Protocol Number: EMR62225-019 Start Date*: 2004-12-30
    Sponsor Name:Merck KGaA
    Full Title: A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from t...
    Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002900-16 Sponsor Protocol Number: CAFQ056A2203 Start Date*: 2007-10-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-...
    Medical condition: The main objective of this study is to assess the efficacy of AFQ056 in reducing L-dopa induced dyskinesias.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004744-31 Sponsor Protocol Number: TR12 Start Date*: 2019-06-24
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis With Nalbuphine ER Tablets for the Treatment ...
    Medical condition: Treatment of Cough in Idiopathic Pulmonary Fibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-016143-19 Sponsor Protocol Number: 09 196 07 Start Date*: 2010-02-23
    Sponsor Name:Michael J. Fox Foundation for Parkinson’s Research
    Full Title: VALIDATION OF DYSKINESIA RATING SCALES
    Medical condition: Maladie de parkinson
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001593-10 Sponsor Protocol Number: EMR 62225-018 Start Date*: 2004-12-02
    Sponsor Name:MERCK S.P.A.
    Full Title: A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from t...
    Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002447-15 Sponsor Protocol Number: SPIMM-301 Start Date*: 2018-06-22
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondr...
    Medical condition: Primary Mitochondrial Myopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) DE (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001722-25 Sponsor Protocol Number: ZonMw80-83600-98-10226 Start Date*: 2013-08-27
    Sponsor Name:VU University Medical Center
    Full Title: Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006270-15 Sponsor Protocol Number: CAFQ056A2206 Start Date*: 2009-03-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Pa...
    Medical condition: L-dopa induced dyskinesias in Parkinson’s patients with severe motor complications
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004892-11 Sponsor Protocol Number: SteP-on Start Date*: 2021-04-22
    Sponsor Name:OSPEDALE SANTA MARIA DELLA MISERICORDIA
    Full Title: A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients
    Medical condition: • Subjects of both genders over 18 years of age, with a clinical diagnosis of idiopathic PD • A Modified Hoehn and Yahr stage of = 4 in the “off” state; • A stable (4 weeks since last modification)...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003738-24 Sponsor Protocol Number: ADS-AMT-PD304 Start Date*: 2015-04-23
    Sponsor Name:Adamas Pharmaceuticals, Inc.
    Full Title: ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia
    Medical condition: Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008712-98 Sponsor Protocol Number: CAFQ056A2208 Start Date*: 2009-05-18
    Sponsor Name:Novartis Pharma AG
    Full Title: 13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...
    Medical condition: moderate to severe levodopa induced dyskinesias in patients with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013916 Dyskinesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001092-39 Sponsor Protocol Number: CAQW051A2209 Start Date*: 2011-06-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesi...
    Medical condition: L-dopa induced dyskinesias in Parkinson’s patients with moderate to severe L-dopa induced dyskinesias
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011736-35 Sponsor Protocol Number: CHUBX 2009/02 Start Date*: 2009-07-27
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomisée versus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur les DYSkinésies induites par la L-Dopa...
    Medical condition: Maladie de Parkinson
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003028-35 Sponsor Protocol Number: CTU/2016/278 Start Date*: 2019-09-04
    Sponsor Name:University College London Comprehensive Clinical Trial Unit
    Full Title: A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-006053-22 Sponsor Protocol Number: NLX-112-DYS-101 Start Date*: 2021-09-22
    Sponsor Name:Neurolixis SAS
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease
    Medical condition: Parkinson´s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-006004-16 Sponsor Protocol Number: 03PDE2020 Start Date*: 2021-07-16
    Sponsor Name:Celon Pharma S.A.
    Full Title: Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Diseas...
    Medical condition: Levodopa-induced dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002627-16 Sponsor Protocol Number: IRL752C003 Start Date*: 2022-07-28
    Sponsor Name:Integrative Research Laboratories Sweden AB (IRLAB)
    Full Title: A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) FR (Completed) ES (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006721-27 Sponsor Protocol Number: CERE-120-06 Start Date*: 2008-10-20
    Sponsor Name:Ceregene Inc.
    Full Title: A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2...
    Medical condition: idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000400-81 Sponsor Protocol Number: S308.2.008 Start Date*: 2009-04-03
    Sponsor Name:Solvay Pharmaceuticals BV
    Full Title: A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s D...
    Medical condition: Advanced Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003884-25 Sponsor Protocol Number: 4202-HEM-301 Start Date*: 2021-06-07
    Sponsor Name:Forma Therapeutics, Inc.
    Full Title: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
    Medical condition: sickle cell disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Temporarily Halted) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 16:05:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA